Stifel analyst Stephen Willey downgraded Vor Bio (VOR) to Hold from Buy with a price target of 30c, down from $5, following the company’s decision to explore a range of strategic alternatives in an effort to maximize shareholder value. The decision reflects a combination of both clinical data evaluated to date and the challenging financing environment currently characterizing the biotech sector, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue